Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) Cost of Revenue (2019 - 2025)

Volitionrx (VNRX) has disclosed Cost of Revenue for 7 consecutive years, with $958567.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 9.02% year-over-year to $958567.0, compared with a TTM value of $4.2 million through Sep 2025, down 30.62%, and an annual FY2024 reading of $5.4 million, down 21.61% over the prior year.
  • Cost of Revenue was $958567.0 for Q3 2025 at Volitionrx, down from $1.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $2.1 million in Q4 2021 and bottomed at $427401.0 in Q1 2021.
  • Average Cost of Revenue over 5 years is $1.4 million, with a median of $1.5 million recorded in 2022.
  • The sharpest move saw Cost of Revenue surged 526.06% in 2021, then crashed 45.16% in 2025.
  • Year by year, Cost of Revenue stood at $2.1 million in 2021, then decreased by 20.93% to $1.7 million in 2022, then increased by 13.15% to $1.9 million in 2023, then crashed by 34.08% to $1.3 million in 2024, then decreased by 23.42% to $958567.0 in 2025.
  • Business Quant data shows Cost of Revenue for VNRX at $958567.0 in Q3 2025, $1.0 million in Q2 2025, and $917299.0 in Q1 2025.